- Benzinga•last year
Insider Roundup While analyst recommendations can be a hit or miss, insider transactions are usually more telling of a company’s future stock behavior. Insiders are major owners and/or management of a ...
- PR Newswire•last year
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has completed its acquisition of Dyax Corp. (DYAX) in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share. Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 for HAE, representing a potential additional $646 million in aggregate contingent consideration. "We are excited to complete the acquisition of Dyax and look forward to working alongside their very talented and committed team to address significant unmet patient need around the world.
- Accesswire•last yearTechnical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Park Lane Advisor has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Dyax Corporation ...
DYAX : Summary for Dyax Corp. - Yahoo Finance
Dyax Corp. (DYAX)
NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
As of 4:00PM EST. Market open.
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|